The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Prevalence, predisposition and prevention of type II diabetes
Open accessAbstract
In 2000, more than 151 million people in the world are diabetic. It is predicted that by 2010, 221 million people and by 2025, 324 million will be diabetic. In the U.S., for the population born in 2000, the estimated lifetime risk for diabetes is more than 1 in 3. The economic and human cost of this disease is devastating. The current cost of diabetes in the U.S. is estimated to be at $132 billion, which includes $92 billion of direct medical costs and $40 billion of indirect costs such as disability, work loss and premature mortality. The outbreak of the current diabetic epidemic has been accompanied by a similarly drastic increase in obesity. The relation between the two is a matter of debate but presumably both are caused by changes in dietary habits and an increasingly sedentary modern lifestyle. Compelling scientific evidence indicates that lifestyle modification effectively prevents or delays the occurrence of type 2 diabetes. Recent clinical trials also demonstrate that success in the treatment of obesity, either surgically or pharmacologically, leads to the prevention of type 2 diabetes among the obese. Clinical data have also revealed that the insulin sensitizing agent troglitazone is efficacious in both β-cell preservation and delaying the onset of type 2 diabetes. Future safe and more effective anti-obesity medicines and insulin sensitizing agents that help to preserve β-cell function, in addition to efforts of lifestyle modification, thus hold promise for the overweight population with potential for reduction in the development of diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“In the Finnish trial [58], 522 middle-aged, overweight with impaired glucose tolerance subjects were randomly assigned to either the intervention group or the control group.”
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“With the current rate of increase, it has been projected that 221 million people will be diabetic in 2010 and 324 million by 2025 [2].”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Since the metformin mechanism of action might be through activation of AMPK [62], a kinase that is activated during exercise [63], it is possible that exercise may act through the same molecular cellular pathway and therefore there are no additive effects of these two treatment regimens.”
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
Clément, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.-M., et al. (1998) · Nature · doi:10.1038/32911 · Cited by 2,346
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“0 kg), but also exhibited a 37% reduction in the incidence of type 2 diabetes during the treatment period [77].”
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“The activated PKC in turn phosphorylates and activates other serine kinases such as IKK-β[32]and JNK-1 [33], leading to phosphorylation of serine sites on IRS-1 insulin receptor substrate (IRS) 1 and 2 at Serine/Threonine sites, blunting the insulin signaling pathway[34].”
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Foster, G. D., Wyatt, H. R., Hill, J. O., McGuckin, B. G., Brill, C., Mohammed, B. S., Szapary, P. O., Rader, D. J., Edman, J. S., & Klein, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022207 · Cited by 1,794
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity
Samaha, F. F., Iqbal, N., Seshadri, P., Chicano, K. L., Daily, D. A., McGrory, J., Williams, T., Williams, M., Gracely, E. J., & Stern, L. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022637 · Cited by 1,267 · cited 1×
“traditional diets [68-70] although their acceptance among official agencies is limited at best.”
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Jackson, R. S., Creemers, J. W. M., Ohagi, S., Raffin-Sanson, M.-L., Sanders, L., Montague, C. T., Hutton, J. C., & O'Rahilly, S. (1997) · Nature Genetics · doi:10.1038/ng0797-303 · Cited by 1,153
Fructose, weight gain, and the insulin resistance syndrome,,
Elliott, S. S., Keim, N. L., Stern, J. S., Teff, K., & Havel, P. J. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.911 · Cited by 1,039
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Boden, G., Sargrad, K., Homko, C., Mozzoli, M., & Stein, T. P. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00006 · Cited by 542
THE INSULIN RESISTANCE SYNDROME: Definition and Dietary Approaches to Treatment
Reaven, G. M. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132155 · Cited by 516 · cited 1×
“Currently, the abnormalities clustered with insulin resistance include some degree of glucose intolerance (either manifested as elevated fasting glucose or impaired glucose tolerance), dyslipidemia (elevated triglycerides, reduced HDL-c, reduced LDL-particle diameter), endothelial dysfunction (increased mononuclear ce…”
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
Gannon, M. C., & Nuttall, F. Q. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2375 · Cited by 428 · cited 1×
“6% [72].”
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Differentiated long-term effects of intentional weight loss on diabetes and hypertension
Sjöström, C. D., Peltonen, M., Wedel, H., & Sjöström, L. (2000) · Hypertension · doi:10.1161/01.hyp.36.1.20 · Cited by 367 · cited 1×
“In another prospective study conducted in Sweden, the Swedish Obese Subjects (SOS) study, compared the incidence of development of diabetes for 346 patients receiving gastric bypass surgery to the same number of obese control subjects receiving "conventional nonpharmacological obesity treatment" [74].”
Volek, J., Sharman, M., Gómez, A., Judelson, D., Rubin, M., Watson, G., Sokmen, B., Silvestre, R., French, D., & Kraemer, W. (2004) · Nutrition & Metabolism · doi:10.1186/1743-7075-1-13 · Cited by 175 · cited 1×
“traditional diets [68-70] although their acceptance among official agencies is limited at best.”
AMP-activated protein kinase: a key system mediating metabolic responses to exercise
HARDIE, D. G. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000106171.38299.64 · Cited by 165
The case for low carbohydrate diets in diabetes management
Arora, S. K., & McFarlane, S. I. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-16 · Cited by 102
Cholesterol and cardiovascular disease
Tyroler, H. A. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90851-8 · Cited by 52 · cited 1×
“The pharmaceutical breakthrough of the statin-class of safe and effective drugs for plasma cholesterol control has caused the mortality rate for cardiovascular disease to decrease [94,95].”
Cited by
Jeong, S.-M., Kang, M.-J., Choi, H.-N., Kim, J.-H., & Kim, J.-I. (2012) · Nutrition Research and Practice · doi:10.4162/nrp.2012.6.3.201 · Cited by 265
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Ca2+ and insulin-mediated glucose uptake
LANNER, J., BRUTON, J., KATZ, A., & WESTERBLAD, H. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.01.006 · Cited by 60
Mideksa, S., Ambachew, S., Biadgo, B., & Baynes, H. W. (2018) · Adipocyte · doi:10.1080/21623945.2018.1467716 · Cited by 30
Metadata
- Authors
- Cheng, D.
- Venue
- Nutrition & Metabolism
- Published
- 2005-10-18
- Volume
- 2
- Issue
- 1
- Pages
- 29-29
- ISSN
- 1743-7075 (ISSN-L)
- OpenAlex
- W1573095123
- Cited by
- 158
- References
- 35
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.